<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00973856</url>
  </required_header>
  <id_info>
    <org_study_id>09025</org_study_id>
    <nct_id>NCT00973856</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands</brief_title>
  <official_title>Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akron General Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akron General Medical Center</source>
  <brief_summary>
    <textblock>
      The objective is to conduct a pilot study to determine the effectiveness of PURELL VF481 to
      treat warts located on the hands.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  At least 5, but not more than 20 participants will be enrolled in the study.

        -  Each wart is randomly assigned a test product prior to the start of the study

        -  Warts are equally distributed between products so that an equal number of warts treated
           on each person. One (1) product will be assigned to each hand to minimize treatment
           confusion for the participants

        -  The test product will be applied to a wooden applicator and gently rubbed into the wart,
           then covered with a latex free adhesive bandage.

        -  Subjects will log date and time of application and anything notable (such as changes in
           wart appearance or missed dose) in a log book.

        -  Measurement of wart (longest diameter) and photos taken at each visit by trained office
           medical assistants, LPNs, PA-C or MD.

        -  Time points for office visitation: Baseline (0 weeks), 4 weeks, 8 weeks, 12 weeks
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in % Reduction in Wart Size Between Product A and Product B at Each Timepoint</measure>
    <time_frame>Baseline, 4, 8, and 12 weeks, change at 12 weeks reported</time_frame>
    <description>Data is not available due to study closure and data destruction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Size of Warts Treated by Each Product at Each Time Point.</measure>
    <time_frame>Baseline, 4, 8 and 12 weeks, change at 12 weeks reported</time_frame>
    <description>Data is not available due to study closure and data destruction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Papillomavirus Infections</condition>
  <condition>Warts</condition>
  <condition>Condylomata Acuminata</condition>
  <condition>Epidermodysplasia Verruciformis</condition>
  <arm_group>
    <arm_group_label>PURELL Left Hand/ Placebo Right Hand</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One product will be assigned to each hand to minimize treatment confusion for the participants.
PURELL VF481 Left Hand/ Placebo Right Hand</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Solution Left Hand/ PURELL Right hand</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One (1) product will be assigned to each hand to minimize treatment confusion for the participants PURELL VF481 Right Hand/ Placebo Left Hand
One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PURELL VF481</intervention_name>
    <description>One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed</description>
    <arm_group_label>PURELL Left Hand/ Placebo Right Hand</arm_group_label>
    <arm_group_label>Placebo Solution Left Hand/ PURELL Right hand</arm_group_label>
    <other_name>PURELL VF481 alcohol based hand gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Solution</intervention_name>
    <description>One (1) pump of product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed</description>
    <arm_group_label>PURELL Left Hand/ Placebo Right Hand</arm_group_label>
    <arm_group_label>Placebo Solution Left Hand/ PURELL Right hand</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with 2+ warts being seen at a Dermatologist's office

          -  2 or more warts on the hands that are located at least 1 cm apart or on separate
             fingers

          -  Warts must have been present for at least 2 months

          -  Wart size must be between 2 mm-15 mm in diameter

          -  Participants must be in good general health

          -  Participants must be able to speak and read in English.

          -  Participant must be able to read and sign participant instruction sheet, and informed
             consent and authorization.

          -  Subjects must be able to understand and execute the instructions presented in
             pictorial form.

        Exclusion Criteria:

          -  Pregnancy (Patients will be asked to verify using criteria of contraception, menstrual
             cycle, and pregnancy test, if necessary).

          -  Treatment of warts with other methods such as salicylic acid, etc., in the past 14
             days.

          -  Known allergies to common topical antimicrobials or the individual ingredients in
             either test product.

          -  Participation in a clinical study in the past 7 days or participation in another
             clinical study

          -  Unwillingness to perform requirements of the study

          -  Any medical condition that should preclude participation in the study, at the
             discretion of the physician

          -  Missed â‰¥ 6 of the treatments in a 4 week study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eliot Mostow, M.D&gt;</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akron General Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Akron Dermatology</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.akrongeneral.org</url>
    <description>Akron General Medical Center</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 8, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <results_first_submitted>July 5, 2017</results_first_submitted>
  <results_first_submitted_qc>July 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2019</results_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Epidermodysplasia Verruciformis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were no pre-assignment details. Once consented, pts were enrolled into both study arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PURELL VF481 Left Hand/ Placebo Right Hand</title>
          <description>Warts are equally distributed between products so that an equal number of warts treated on each person. One (1) product will be assigned to each hand to minimize treatment confusion for the participants
PURELL VF481: One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed</description>
        </group>
        <group group_id="P2">
          <title>Placebo Solution Left Hand/ PURELL VF481 Right Hand</title>
          <description>Warts are equally distributed between products so that an equal number of warts treated on each person One (1) product will be assigned to each hand to minimize treatment confusion for the participants
One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
Placebo Comparator: One (1) pump of product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PURELL VF481 Left Hand/ Placebo Right Hand</title>
          <description>Warts are equally distributed between products so that an equal number of warts treated on each person. One (1) product will be assigned to each hand to minimize treatment confusion for the participants
PURELL VF481: One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed</description>
        </group>
        <group group_id="B2">
          <title>Placebo Solution Left Hand/ PURELL VF481 Right Hand</title>
          <description>Warts are equally distributed between products so that an equal number of warts treated on each person. One (1) product will be assigned to each hand to minimize treatment confusion for the participants
One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
Placebo Comparator: One (1) pump of product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>warts</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>warts</units>
          <param>Count of Units</param>
          <units_analyzed>warts</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="3"/>
                <count group_id="B2" value="2"/>
                <count group_id="B3" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>warts</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="5"/>
                <count group_id="B2" value="5"/>
                <count group_id="B3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>warts</units>
          <param>Count of Units</param>
          <units_analyzed>warts</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="3"/>
                <count group_id="B2" value="2"/>
                <count group_id="B3" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>warts</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="5"/>
                <count group_id="B2" value="5"/>
                <count group_id="B3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sex/Gender unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="0"/>
                <count group_id="B2" value="0"/>
                <count group_id="B3" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>warts</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="5"/>
                <count group_id="B2" value="5"/>
                <count group_id="B3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>warts</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="3"/>
                <count group_id="B2" value="2"/>
                <count group_id="B3" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>warts</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="5"/>
                <count group_id="B2" value="5"/>
                <count group_id="B3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in % Reduction in Wart Size Between Product A and Product B at Each Timepoint</title>
        <description>Data is not available due to study closure and data destruction</description>
        <time_frame>Baseline, 4, 8, and 12 weeks, change at 12 weeks reported</time_frame>
        <population>Data is not available due to study closure and data destruction</population>
        <group_list>
          <group group_id="O1">
            <title>Purell VF481</title>
            <description>Active Ingredient: 70% ethanol</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in % Reduction in Wart Size Between Product A and Product B at Each Timepoint</title>
          <description>Data is not available due to study closure and data destruction</description>
          <population>Data is not available due to study closure and data destruction</population>
          <units_analyzed>wart reduction %</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>wart reduction %</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Size of Warts Treated by Each Product at Each Time Point.</title>
        <description>Data is not available due to study closure and data destruction</description>
        <time_frame>Baseline, 4, 8 and 12 weeks, change at 12 weeks reported</time_frame>
        <posting_date>07/2020</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>Same definition</desc>
      <group_list>
        <group group_id="E1">
          <title>Purell VF481</title>
          <description>Active Ingredient: 70% ethanol</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>15% alcohol formulation that aesthetically resembles VF481</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eliot Mostow, MD</name_or_title>
      <organization>Cleveland Clinic Akron General</organization>
      <email>emostow@akronderm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

